Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan;93(1):110-111.
doi: 10.1002/jmv.26179. Epub 2020 Jun 24.

Use of amantadine in a patient with SARS-CoV-2

Gonzalo Emiliano Aranda-Abreu  1 , José Dolores Aranda-Martínez  2 , Ramiro Araújo  3
Affiliations
Case Reports

Use of amantadine in a patient with SARS-CoV-2

Gonzalo Emiliano Aranda-Abreu et al. J Med Virol. 2021 Jan.
No abstract available

PubMed Disclaimer

References

    1. Aranda Abreu GE, Hernández Aguilar ME, Herrera Covarrubias D, Rojas Durán F. Amantadine as a drug to mitigate the effects of COVID‐19. Med Hypotheses. 2020;140:109755. - PMC - PubMed
    1. Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID‐19, including ARDS and to reduce viral replication through lysosomal effects [published online ahead of print May 21, 2020]. J Med Virol. 10.1002/jmv.26030 - DOI - PMC - PubMed
    1. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3:e208857. - PMC - PubMed
    1. Cortés Borra A. Does amantadine have a protective effect against COVID‐19 [published online ahead of print June 04, 2020]. Neurol Neurochir Pol. 10.5603/PJNNS.a2020.0041 - DOI - PubMed